FiercePharma

Vertex Submits Application for Priority Review and Approval of KALYDECOTM (VX-770, ivacaftor) in the U.S. as First Potential Med

Vertex Submits Application for Priority Review and Approval of KALYDECO TM (VX-770, ivacaftor) in the U.S. as First Potential Medicine to Target the Underlying Cause of Cystic Fibrosis -- Accelerated ...
FierceBiotech

Vertex Submits Applications in the U.S. and Europe for Approval of Lumacaftor in Combination with Ivacaftor for People with Cystic Fibrosis Who Have Two Copies of the F508del ...

BOSTON--Vertex Pharmaceuticals Incorporated (VRTX) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) and a Marketing Authorization ...